Adc Therapeutics SA Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$80.9Mnext fiscal year
FY EPS (est.)
-$0.86next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Planned sBLA Submission for ZYNLONTA plus Rituximab | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
ZYNLONTA Net Product Revenue Quarterly20MTarget: Accelerated growth trajectory starting in 2027
Cash and Cash Equivalents Quarterly231MTarget: Cash runway at least into 2028
Total Adjusted Operating Expenses Quarterly42.9MTarget: Continued cost discipline to extend cash runway
Watch Items
- FDA Regulatory Review of LOTIS-5 sBLATrigger: Pre-sBLA meeting in August 2026 and planned sBLA submission in Q4 2026Action: Monitor FDA feedback regarding the benefit-risk profile of ZYNLONTA plus rituximab, particularly safety concerns in patients aged 75 years or older.
- LOTIS-7 Phase 1b Trial Data ReadoutTrigger: Full data sharing at a medical meeting and publication by end of 2026Action: Evaluate efficacy and safety of ZYNLONTA in combination with glofitamab to determine potential regulatory and compendia pathways.
Research as of 19 Jun 2026